BioSpace News Archive

Endo International plc announced that its subsidiaries, Endo Ventures Limited, Par Pharmaceutical, Inc.

Tolero Pharmaceuticals, Inc. announced that new data from five abstracts on the company’s pipeline of investigational agents will be presented at the American Association for Cancer Research Annual Meeting, taking place March 29-April 3, 2019 in Atlanta, Georgia.

InkSpace Imaging, a medical device startup based out of the University of California, Berkeley has closed its first round of private funding, securing funds for continued growth of the company.

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Syneos Health, Inc. resulting from allegations that Syneos and/or its executives may have issued materially misleading business information to the investing public.

Nektar Therapeutics announced several preclinical data presentations for its immuno-oncology pipeline candidates, bempegaldesleukin*, a CD122-preferential IL-2 pathway agonist, and NKTR-255, an IL-15 receptor agonist, at the American Association for Cancer Research Annual Meeting 2019, which is being held from March 29 to April 3, 2019 at the Georgia World Congress Center in Atlanta, Georgia.

Consolidated Results of Operations, As Reported and As Adjusted - Three-month periods ended December 31, 2018 and 2017:

First in-human Clinical Presentation of Company’s PNK Allogeneic Cell Therapy in Patients with Acute Myeloid Leukemia

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Health Insurance Innovations, Inc. of the April 22, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Vasayo is pleased to announce the first member of its Board of Directors, Maria Fiorini Ramirez, the woman The Wall Street Journal once rated as the world’s foremost financial forecaster.

Syros Pharmaceuticals announced that it will present new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 inhibitor currently in a Phase 1 clinical trial focused on ovarian and breast cancers, and on SY-5609, its selective oral CDK7 inhibitor that the company has named as its next development candidate, at the American Association for Cancer Research Annual Meeting taking place March 29-April 3 in Atlanta.